In a recent study, Li et al. demonstrated that STM108, a glycosylation-specific mAb targeting gPD-L1, induces gPD-L1 internalization, effectively inhibits the PD-1/PD-L1 axis, and enhances anti-tumor immunity in mice. Here, PDCD1 is linked to neoplasm.